- Presentation of the latest results on glenzocimab in Stroke
patients
Regulatory News:
ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical-stage
biotechnology company focused on the development of innovative
drugs for the treatment of cardiovascular emergencies, in
particular stroke, announced today that it participates in the 15th
World Stroke Congress (WSC) on October 10 -12, 2023 in Toronto,
Canada.
The 15th World Stroke Congress (WSC 2023), organized by The
World Stroke Organization and the Canadian Stroke Consortium, is
the international leading conference on Stroke Research and
publication of major clinical trial data. This 3-day congress
brings together international opinion leaders to discuss the latest
advances in stroke care.
At this international conference, the Company presented three
communications on glenzocimab clinical development
1) Oral Presentation, by Pr Carlos Molina, MD, Spain
“Glenzocimab treatment on top of thrombolysis and mechanical
thrombectomy in elderly patients is associated with a favorable
outcome at 24 hours and 90 days.” By Carlos Molina et al. Abstract
1927. Oct 10th, 2023.
This communication underlines the potential of glenzocimab
treatment for yielding a favorable outcome for those stroke
patients from the ACTIMIS study, aged over 65 years and treated by
mechanical thrombectomy, that represent a real therapeutic
challenge in acute ischemic stroke. On this elderly patient’s
subpopulation treated with glenzocimab, a 4-fold reduction of mRS
4-6 (i.e., death and severe disability) was observed, as well as an
increase in the percentage of patients presenting with mRS 0-2
(i.e., favorable outcome without any assistance) compared to
placebo (standard of care alone).
2) E-Poster Presentation, by Dr James Grotta, MD,
USA:
“ACTISAVE: glenzocimab efficacy study in ischemic stroke - a
blinded safety data review of the first 100 patients recruited.” By
Martin Koehrmann et al. Abstract 2211. Oct 12th, 2023.
This e-poster presents the design of the phase 2/3 ACTISAVE
study and the blind safety data from the first 100 patients
included.
3) e-Poster Viewing, by Adeline Meilhoc, PsyD, France
“Identifying best responders to glenzocimab in Acute Ischemic
Stroke (AIS) with Artificial Intelligence (AI): an ACTIMIS
sub-analysis.” By Adeline Meilhoc et al. Abstract 2124.
This sub-analysis of ACTIMIS study using Artificial Intelligence
allowed the identification of several groups of glenzocimab best
responding patients.
Sophie BINAY, General Manager and Chief Scientific Officer,
stated: "These three presentations delivered at this world
leading conference for stroke research underline the significant
role played by Acticor Biotech in this ecosystem, as well as the
urgent need for new innovative treatments in stroke. We are now
looking forward to the final clinical results of our phase 2/3
ACTISAVE study for the treatment of stroke, which are expected as
early as in the second quarter of 2024.”
About WSO and WSC:
The World Stroke Organization (WSO) has a mission to reduce the
global burden of stroke through prevention, treatment and long-term
care. WSO is approved by the World Health Organization (WHO) as a
non-governmental organization for official relations.
The World Stroke Organization is the only global body solely
focused on stroke.
It was established in October 2006 through the merger of the
International Stroke Society and the World Stroke Federation with
the purpose of ensuring a life free from stroke. With around 4000
individual and 90 society members spanning every global region, WSO
represents over 55,000 stroke specialists in clinical, research and
community settings.
The 15th World Stroke Congress (WSC 2023) held in Toronto from
October 10-12, 2023, is organized by The World Stroke Organization
and the Canadian Stroke Consortium with accessible online
components.
About ACTICOR BIOTECH
Acticor Biotech is a clinical stage biopharmaceutical company, a
spin-off from INSERM (the French National Institute of Health and
Medical Research), which is aiming to develop an innovative
treatment for cardiovascular emergencies, including ischemic
stroke.
In May 2022, Acticor Biotech presented positive results from its
Phase 1b/2a study, ACTIMIS, confirming the safety profile and
showing a reduction in mortality and intracerebral hemorrhage in
the glenzocimab-treated group in patients with stroke. The efficacy
of glenzocimab is now being evaluated in an international Phase 2/3
study, ACTISAVE, which will include 400 patients, with clinical
results expected in Q2 2024. In July 2022, Acticor Biotech was
granted "PRIME" status by the European Medicines Agency (EMA) for
glenzocimab in the treatment of stroke. This designation will allow
the company to strengthen its interactions and obtain early
dialogues with regulatory authorities.
Acticor Biotech is supported by a panel of European and
international investors (Mediolanum farmaceutici, Karista, Go
Capital, Newton Biocapital, CMS Medical Venture Investment (HK)
Limited, A&B (HK) Limited, Anaxago, and the Armesa foundation).
Acticor Biotech is listed on Euronext Growth Paris since November
2021 (ISIN: FR0014005OJ5 – ALACT).
For more information, visit: www.acticor-biotech.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231012040468/en/
ACTICOR BIOTECH Gilles AVENARD, MD General Manager and
founder gilles.avenard@acticor-biotech.com T. : +33 (0)6 76 23 38
13
Sophie BINAY, PhD Chief Operating Officer and Scientific
Director Sophie.binay@acticor-biotech.com T. : +33 (0)6 76 23 38
13
NewCap Mathilde BOHIN / Quentin MASSÉ Investor Relations
acticor@newcap.eu T. : +33 (0)1 44 71 94 95
NewCap Arthur ROUILLÉ Media Relations acticor@newcap.eu
T. : +33 (0)1 44 71 00 15
Acticor Biotech (EU:ALACT)
Historical Stock Chart
From Apr 2024 to May 2024
Acticor Biotech (EU:ALACT)
Historical Stock Chart
From May 2023 to May 2024